Healthcare, Pharma & Life Sciences

Rossville, Md. – October 28, 2026 -- LifeLogics, a nonprofit technology company serving the organ and tissue donation and transplantation community, has appointed Ankit Mathur as Chief Executive Officer. Mathur, who has more than two decades of experience in technology, healthcare and organizational leadership, most recently served as Chief Technology Officer of United Network for Organ Sharing (UNOS).

Mathur's mandate centers on platform modernization and interoperability

Mathur will lead LifeLogics through what the company calls its next phase of growth and modernization. His priorities are strengthening partnerships with organ procurement organizations (OPOs), advancing the company's technology platforms, improving customer experience and expanding interoperability across the donation ecosystem.

WASHINGTON – October 28, 2026 -- The Heart Failure Society of America (HFSA) has called for right heart failure (RHF) to be recognized as a distinct clinical syndrome rather than a secondary complication of left-sided heart disease, in a Scientific Statement published in the Journal of Cardiac Failure.

The statement, titled Right Heart Failure: An HFSA Scientific Statement, consolidates current evidence into a structured framework for earlier recognition and more consistent management. It cites longer hospitalizations, heavier ICU use and frequent readmissions as consequences that strain the healthcare system.

Columbus, Ohio – October 28, 2026 -- The Perfect Companion plans to hire 25 more employees in Columbus, adding to a local team of 65, as Ohio works to fill an estimated 17,000 home care aide openings every year. The private-pay senior care provider marks five years in the city this month.

Columbus office has grown to 65 staff since its October 2021 opening

Concierge Care Director Debra Banchefsky has led the Columbus office since it opened. The company provides non-medical in-home care, from companionship to help with daily routines, for older adults in Columbus and surrounding suburbs.

It matches caregivers to clients through a proprietary assessment that weighs personality as well as skill. It trains caregivers to a Ritz-Carlton hospitality standard and staffs its phones with a live person 24 hours a day, every day of the year. The company has never franchised.

LOUISVILLE – October 28, 2026 -- US WorldMeds Ventures, LLC has acquired Orbus Therapeutics, Inc., adding a late-stage eflornithine program for recurrent Grade 3 astrocytoma. In a prespecified subset of the Phase 3 STELLAR study, patients with IDH-mutant disease reached median overall survival of 34.9 months, versus 23.5 months on lomustine alone.

US WorldMeds made an undisclosed upfront payment under a definitive merger agreement. Orbus is eligible for development, regulatory and sales-based milestone payments, plus tiered royalties on U.S. net sales. It is now a wholly owned subsidiary of US WorldMeds.

STELLAR missed its primary endpoint in the full study population

The 343-patient trial compared eflornithine plus lomustine with lomustine alone in recurrent Grade 3 astrocytoma, defined under the 2016 WHO classification. It showed no overall survival difference between arms in the intent-to-treat population, which was the primary endpoint.

TORRINGTON – October 28, 2026 -- Therap Services has added a Personalized Sleep Insights feature to its Therap Connect platform. It analyzes three months of historical data from Withings sleep monitors and Watchdog room sensors to help care teams identify the room conditions that support better sleep.

Sleep start times are matched against room temperature and humidity

The module combines ambient room monitoring with sleep tracking data. By comparing when an individual falls asleep with room temperature and humidity, the system highlights optimal environmental conditions for that person. Care teams can use the output for proactive care planning and data-informed adjustments to the sleeping environment.

ATLANTA – October 28, 2026 -- Providi has launched as the corporate brand of the company behind electronic health record (EHR) products Cerbo and OptiMantra, which together serve nearly 7,000 cash-pay personalized care clinics.

The two companies combined in 2025 with a growth investment from Mainsail Partners. Cerbo and OptiMantra remain as product brands under Providi. Both have served the market since 2011.

Providi's combined products cover eight cash-pay care segments

The EHR and practice management products support functional, integrative, longevity, wellness, direct primary care, concierge, med spa and behavioral health practices.

Rockville, Md. – October 28, 2026 -- The Agency for Healthcare Research and Quality (AHRQ) is committing $7.5 million over three years to a sepsis quality improvement partnership with the Indian Health Service (IHS), covering IHS emergency care facilities.

Initiative targets early sepsis identification in IHS emergency care

The program will strengthen early identification and management of sepsis. It is designed around the needs, resources, cultural values and traditions of American Indian and Alaska Native communities, and follows three years of consultation with those communities.

IHS has identified a need to improve sepsis diagnosis and management across its facility network. Many of its sites are in rural or remote locations where access to specialty expertise and other resources may be limited.

Edinburgh – October 28, 2026 -- Excelra has taken over the bioinformatics services of Fios Genomics Ltd and the Edinburgh team behind them, effective 20 October 2026. The move adds omics analytics capacity to the scientific informatics company's UK and European operations.

Fios team joins Excelra's scientific consulting group

The Fios scientists become part of Excelra's wider scientific consulting group. They will keep serving existing Fios clients on the same platform, according to the companies. The announcement does not disclose financial terms.

Fios was founded in 2008 as a University of Edinburgh spin-out. It has spent nearly two decades analysing genomics, transcriptomics and multi-omics studies for pharma, biotech and other life science researchers.

Dusseldorf – October 28, 2026 -- Germany's industrial health economy generated about EUR 101.5 billion in gross value added in 2025, but slow certification and thin growth capital are keeping innovations out of clinical practice, according to a new paper from the Innovationsrat Deutschland.

The sector employs roughly one million people and accounts for about 7 percent of German exports. More than half of the medical device manufacturers surveyed in a study commissioned by the European Commission wait over 19 months for certification under the EU Medical Device Regulation.

Kirkland, Wash. – October 28, 2026 -- EIT Pharma has appointed Dr. Joseph Toerner, a 26-year veteran of the U.S. Food and Drug Administration (FDA), as Chief Medical Officer, effective immediately, while its lead hepatitis D candidate lonafarnib is under regulatory review.

Former FDA hepatology director takes clinical lead on two programs

Toerner will provide medical and clinical leadership across EIT Pharma's development programs. That includes supporting the ongoing regulatory review of lonafarnib, a late-stage, first-in-class oral therapy for chronic hepatitis D (CHD), and peginterferon lambda, a Phase 2 treatment for severe acute viral respiratory infections.

EIT Pharma describes lonafarnib as the only oral therapeutic candidate in late-stage clinical development for CHD. The drug has not been approved by the FDA or any other regulatory authority, and its safety and efficacy have not been established.